Zeitschrift fur Rheumatologie最新文献_第5页

[Aphthous ulcers in a patient of Turkish descent : A diagnostic challenge]. [土耳其裔患者的阿弗他溃疡：诊断难题]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-03-18 DOI: 10.1007/s00393-024-01498-8

Kathrin Standfest, Vanessa Bartsch, Manuela Beckert, Axel J Hueber

引用次数: 0

Anakinra in idiopathic recurrent pericarditis: a comprehensive case series and literature review. 用于特发性复发性心包炎的 Anakinra：综合病例系列和文献综述。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-01-26 DOI: 10.1007/s00393-023-01471-x

Zeynep Toker Dincer, Sejla Karup, Erkin Yilmaz, Osman Corbali, Feyza Nur Azman, Melike Melikoglu, Serdal Ugurlu

{"title":"Anakinra in idiopathic recurrent pericarditis: a comprehensive case series and literature review.","authors":"Zeynep Toker Dincer, Sejla Karup, Erkin Yilmaz, Osman Corbali, Feyza Nur Azman, Melike Melikoglu, Serdal Ugurlu","doi":"10.1007/s00393-023-01471-x","DOIUrl":"10.1007/s00393-023-01471-x","url":null,"abstract":"Objective: Idiopathic recurrent pericarditis (IRP) is defined by recurring episodes of pericardial inflammation without a known cause. This study investigates the safety and efficacy of anakinra, an interleukin‑1 inhibitor, as a successful therapy for IRP in cases resistant to conventional treatment.Methods: A retrospective evaluation of patients treated at our autoinflammatory center between 2011 and 2023 was conducted. Patient files were examined for demographic, clinical, and treatment response data, including nonsteroid anti-inflammatory drugs (NSAIDs), corticosteroids, and colchicine. Monogenic autoinflammatory disease screening was performed for Mediterranean Fever (MEFV), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase (MVK), nucleotide-binding domain, leucine-rich-containing family, pyrin domain-containing-3 (NLRP3), and nucleotide-binding oligomerization domain-containing protein 2 (NOD2). Patients who experienced multiple episodes of pericarditis were diagnosed with recurrent pericarditis. The study evaluated anakinra treatment in IRP patients unresponsive to conventional therapy.Results: The study included 21 participants, 9 (42.9%) female and 12 (57.1%) male. The average age of the participants was 43.1 ± 16.5 years. The MEFV mutation analysis revealed that 2 (9.5%) had a mutation in exon 10 and 4 (19.0%) had one in exon 2. Out of the 16 cases, 15 successfully discontinued steroid treatment. Four patients (19.0%) experienced injection site reactions. C‑reactive protein (CRP) levels were measured at an average of 196 ± 67.8 mg/l before and 2.6 ± 3.15 mg/l after anakinra treatment.Conclusion: In conclusion, the study adds to the growing evidence for the efficacy of interleukin-1 inhibitors, such as anakinra, as a promising treatment modality for IRP in cases resistant to conventional treatment.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"587-596"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139564724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rheumatology in Germany in the SARS-CoV-2 pandemic]. [SARS-CoV-2大流行期间德国的风湿病学]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-09-30 DOI: 10.1007/s00393-024-01573-0

Hans-Iko Huppertz, Ulf Müller-Ladner, Christof Specker

引用次数: 0

[The German Society for Rheumatology and Clinical Immunology (DGRh) and the COVID-19 pandemic]. [德国风湿病学和临床免疫学学会（DGRh）与 COVID-19 大流行病]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1007/s00393-024-01540-9

Anna Julia Voormann, Christof Specker

引用次数: 0

Mitteilungen der DRL. DRL 的通信。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 DOI: 10.1007/s00393-024-01574-z

引用次数: 0

[Course of the COVID-19 pandemic in pediatric rheumatological patients in Germany during the first 3 years (2020-2022)]. [头三年（2020-2022 年）COVID-19 在德国儿童风湿病患者中的流行过程]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-06-06 DOI: 10.1007/s00393-024-01515-w

Ariane Klein, Hans-Iko Huppertz, Gerd Horneff

{"title":"[Course of the COVID-19 pandemic in pediatric rheumatological patients in Germany during the first 3 years (2020-2022)].","authors":"Ariane Klein, Hans-Iko Huppertz, Gerd Horneff","doi":"10.1007/s00393-024-01515-w","DOIUrl":"10.1007/s00393-024-01515-w","url":null,"abstract":"Coronavirus disease 2019 (COVID-19) has influenced the world over the last 3 years. Although the risk of a severe course is low in children, it can be influenced by chronic rheumatic diseases or treatment with immunosuppressive drugs or immunomodulatory medication. The German register for biologics in pediatric rheumatology (BIKER) documented systematic data from 68 centers on the occurrence, presentation and outcome of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in children with rheumatic diseases. Between March 2020 and December 2022, a total of 927 SARS-CoV‑2 infections in 884 patients could be reported and analyzed in pediatric patients with rheumatic diseases. Juvenile idiopathic arthritis (JIA) was the most frequent diagnosis (716 infections) followed by genetic autoinflammation (103 infections), systemic autoimmune diseases (78 infections), idiopathic uveitis (25 infections) and vasculitis (5 infections). Only four patients were treated as inpatients. A 3.5-year-old female patient died during the first wave from encephalopathy and respiratory failure. The patient was treated with methotrexate (MTX) and steroids for systemic JIA. Genetic tests revealed a previously unknown congenital immune defect. No other patient had to be ventilated or treated on the intensive care unit. A case of uncomplicated pediatric inflammatory multisystem syndrome (PIMS) was registered in a patient with JIA treated with MTX. At the time of the infection over 60% of the patients were treated with standard disease modifying antirheumatic drugs (DMARD) and/or biologics. Although the patients treated with MTX showed a slightly longer duration of symptoms, the antirheumatic treatment did not appear to have a negative influence on the severity or outcome of the SARS-CoV‑2 infection.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"528-535"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141284819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[The German COVID-19 rheumatism register]. [德国 COVID-19 风湿病登记册]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-05-30 DOI: 10.1007/s00393-024-01516-9

Rebecca Hasseli, Anne C Regierer, Anja Strangfeld, Alexander Pfeil

{"title":"[The German COVID-19 rheumatism register].","authors":"Rebecca Hasseli, Anne C Regierer, Anja Strangfeld, Alexander Pfeil","doi":"10.1007/s00393-024-01516-9","DOIUrl":"10.1007/s00393-024-01516-9","url":null,"abstract":"At the beginning of the coronavirus disease 2019 (COVID-19) pandemic in December 2019 there was no available evidence regarding the management of immunosuppressive or immunomodulatory treatment and the potential outcomes of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infections in inflammatory rheumatic diseases (IRD). As a result, the Justus Liebig University of Giessen, Germany, in collaboration with the German Society for Rheumatology, established the German COVID-19 register ( www.covid19-rheuma.de ). The COVID-19 register enabled for the first time a systematic documentation and evaluation of viral infections in patients with IRD. The data collection started as early as March 2020. Currently, the register is one of the largest global registers in the field of COVID-19 and IRD. As of 18 December 2023 the register has recorded more than 7100 cases. The first scientific findings on SARS-CoV‑2 infections in IRD patients were generated from the register in 2020, showing an association between disease activity of IRD, certain comorbidities, such as cardiovascular diseases and treatment with rituximab, with an unfavorable course. The contents and construction of the database of the register were designed at the conception to allow collaboration and data exchange with other national and international registers (e.g., EULAR COVID-19 register, COVID-19 global rheumatology alliance and the Lean European open survey on SARS-CoV‑2 infected patients). In addition, other registers and surveys were initiated. A vaccination register documents the tolerability and possible adverse reactions to COVID-19 vaccination in IRD patients. The data resulted in numerous publications and formed the basis for national and international recommendations for action in the care and vaccination of IRD patients during the COVID-19 pandemic. In summary, the German COVID-19 register has made a significant contribution to the understanding of the course of COVID-19 in IRD patients and has facilitated international collaboration for a better understanding of COVID-19 and IRD.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":"536-543"},"PeriodicalIF":0.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Mitteilungen der DGRh - Veranstaltungen der Rheumaakademie. DGRh 的公告 - 风湿病研究院的活动。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 DOI: 10.1007/s00393-024-01572-1

引用次数: 0

[Corona vaccination under immunosuppression]. [免疫抑制下的电晕疫苗接种]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-09-01 Epub Date: 2024-09-23 DOI: 10.1007/s00393-024-01555-2

R Hasseli-Fräbel, C Kneitz, R E Voll, B F Hoyer

引用次数: 0

[Update on treatment of ANCA-associated vasculitis]. [ANCA相关性血管炎治疗的最新进展]。

IF 0.9 4区医学

Zeitschrift fur Rheumatologie Pub Date : 2024-08-28 DOI: 10.1007/s00393-024-01548-1

Julia U Holle, Frank Moosig

{"title":"[Update on treatment of ANCA-associated vasculitis].","authors":"Julia U Holle, Frank Moosig","doi":"10.1007/s00393-024-01548-1","DOIUrl":"https://doi.org/10.1007/s00393-024-01548-1","url":null,"abstract":"This article summarizes the current guidelines and recommendations published by the European Alliance of Associations for Rheumatology (EULAR), the Kidney Disease Improving Global Outcomes (KDIGO) and the American College of Rheumatology (ACR). In addition to glucocorticoids (GC), treatment with biologics is nowadays an established option to treat Anti-Neutrophil Cytoplasmic Antibody (ANCA)-associated vasculitis (AAV). Rituximab (RTX) is used for remission induction and maintenance in organ-threatening and non-organ-threatening granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). For eosinophilic GPA (EGPA) anti-interleukin 5 (IL5) strategies are an important component of treatment for remission induction and maintenance of refractory or relapsing non-organ-threatening diseases in conjunction with GC. The dosing of GC for remission induction in GPA and MPA is now lower than was previously used and additionally, avacopan is approved as a new GC-sparing medication for GPA and MPA over 52 weeks. Conventional strategies, such as cyclophosphamide (CYC) are important for remission induction in severe or refractory organ-threatening disease for all AAVs. The use of methotrexate (MTX) and azathioprine (AZA) is becoming less prominent. The most important unanswered questions in the treatment of AAVs are with respect to the duration of remission maintenance treatment and the individualized treatment guidance based on biomarkers.","PeriodicalId":23834,"journal":{"name":"Zeitschrift fur Rheumatologie","volume":" ","pages":""},"PeriodicalIF":0.9,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142081881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0